1. Labetalol, a compound with both a-and / ?-adrenoreceptor-blocking actions, was given intravenously (13-2.0 mg/kg) in twenty recumbent hypertensive patients.
Introduction
Labetalol (AH5158, Allen and Hanbury Ltd) is a drug with both a-and padrenoreceptor-blocking actions (Boakes, Knight & Richard, 1971 ; Richards, Woodings, Stephens & Maconochie, 1974) Joekes, 1975; Rosei, Brown, Lever, Robertson & Trust, 1975; Rosei, Brown, Fraser, Lever, Morton, Robertson & Trust, 1976a, b) . We report here the effects of labetalol given intravenously on blood pressure, heart rate and plasma concentrations of angiotensin 11 and aldosterone in a series of twenty hypertensive subjects.
Methods
Of the twenty hypertensive patients studied, three were in the malignant phase with bilateral retinal haemorrhages, exudates and papilloedema; sixteen were untreated, or had had all treatment, including diuretics, withdrawn for at least 4 weeks. None was pregnant or receiving oral contraceptives, liquorice or carbenoxolone. Four patients were receiving various anti-hypertensive agents [methyldopa (one), bethanidine (two), frusemide (one), bendrofluazide (one)] when labetalol was given, although blood pressure was not controlled (range 232/170 to 1801 120 mmHg). Four of the twenty, previously untreated, had received propranolol (10 mg intravenously) 2 days before labetalol as part of the cross-over comparison of these drugs (see below). All were recumbent for at least 30 min before labetalol (1.5-2.0 mg/kg) was given, and for up to 3 h afterwards. Four received labetalol as a single rapid bolus;
in sixteen it was given slowly over 10 min. Blood pressures were recorded throughout with a standard sphygmomanometer; peripheral venous blood was withdrawn through an indwelling plastic cannula for estimation of the plasma concentrations of angiotensin I1 (Dusterdieck & McElwee, 1971 ) and aldosterone (Fraser, Guest & Young, 1973) eighteen of the twenty. In five patients, whose informed consent was obtained, the effects of 10 mg of propranolol intravenously were compared with those of labetalol. In four of these patients, propran-0101 was given 2 days before labetalol, in one, 3 days later, dietary sodium and potassium intake being closely similar on the two occasions.
pressure in all twenty patients, the effect being maintained at 3 h in eighteen and for 24 h in four. The greatest fall in blood pressure was from 188/142
to W/64 mmHg within 10 min of 100 mg of labetalol.
Postural hypotension was common, however, and patients were allowed out of bed only under supervision. Labetalol caused significant and sustained reduction in heart rate (Table l), though pulse rates below 60/min were uncommon; the lowest pulse rate in the present series was 48/min, 10 min after 100 mg of labetalol.
Results
Detailed results are given in Table 1 Table) or propranolol versus labetalol (lower Table) In the five patients receiving both labetalol and propranolol, labetalol (100-125 mg) produced a significant reduction in arterial pressure whereas propranolol(l0 mg) did not. By contrast, proprano-101, but not labetalol, lowered plasma angiotensin 11. Both drugs reduced the heart rate; neither affected plasma aldosterone significantly.
Discussion
Labetalol given intravenously is highly effective for the acute reduction of blood pressure. In this series no serious side effects were encountered, and the drug seems particularly suitable for use in hypertensive emergencies. Nevertheless, rapid lowering of pressure in some hypertensive subjects can cause cerebral infarction (Graham, 1975) and therefore labetalol should be used cautiously. Labetalol also caused reductions in heart rate and in plasma concentrations of angiotensin I1 and aldosterone, most clearly seen when these were initially high. Blood pressure reduction could, however, be independent of falls in angiotensin 11, and probably resulted largely from a-adrenoreceptor blockade, causing peripheral vasodilatation.
